Beeline Holdings sells $1.2 million in stock, totals $14.5 million since March
Daniel Rabinowitz, the Secretary and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), recently sold shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The transactions, which took place on March 17, involved the sale of 928 shares at prices ranging from $146.0277 to $149.74 per share, totaling $135,521. The molecular diagnostics company, now valued at over $20 billion, has seen its stock surge 62% over the past year amid strong revenue growth of 57%.
Following these transactions, Rabinowitz holds 224,185 shares of Natera. The sales were conducted to meet tax withholding and remittance obligations related to the vesting of restricted stock units, as noted in the filing. These transactions were executed under a prearranged trading plan that complies with Rule 10b5-1. According to InvestingPro analysis, Natera maintains a healthy liquidity position with a current ratio of 4.0, though the stock appears overvalued at current levels. Subscribers can access 12 additional exclusive ProTips and comprehensive valuation metrics in the Pro Research Report.
In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, which exceeded Wall Street expectations with a narrower-than-anticipated loss per share and higher revenue. The company posted an actual EPS of -$0.41, surpassing the forecasted -$0.49, and reported revenue of $476 million against a predicted $409.89 million. This represented a 53% year-over-year revenue growth, with significant improvements in gross margins, which rose to 63% from 51% the previous year. Analysts at TD Cowen and Canaccord Genuity maintained their Buy ratings on Natera, with both firms setting a price target of $195, citing strong sales projections and strategic operational expenditures.
In addition to financial performance, Natera initiated the HEROES clinical trial to explore treatment de-escalation in metastatic HER2+ breast cancer patients. The trial, sponsored by Unicancer and funded by the French Ministry of Health, aims to investigate the feasibility of ceasing or reducing anti-HER2 targeted therapy in patients who test negative for circulating tumor DNA. Meanwhile, Canaccord Genuity highlighted Natera’s consistent positive operating cash flows and the company’s robust growth levers, such as the expected rise in Signatera’s price and volume.
The analysts also noted the potential benefits from improved Medicare Advantage rates and biomarker legislation expected in 2025. These developments, along with Natera’s strategic spending on operational expenses and the introduction of new clinical evidence, suggest a promising outlook for the company’s future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.